Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
Identifieur interne : 001769 ( Istex/Corpus ); précédent : 001768; suivant : 001770Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
Auteurs : James E. Crowe Jr.Source :
- Vaccine [ 0264-410X ] ; 1998.
English descriptors
- Teeft :
- Adult bone marrow transplant recipients, Antibody, Antibody response, Antibody responses, Antigenic, Antigenic variation, Attenuated, Attenuated influenza, Attenuated vaccines, Belshe, Bronchiolitis, Chanock, Chiba, Cotton rats, Crowe, Cytotoxic, Epidemiol, Experimental infection, Experimental studies, Glezen, Glycoprotein, Heterosubtypic immunity, High levels, Hlnl, Immun, Immune, Immune response, Immune responses, Immunity, Immunization, Immunogenicity, Immunoglobulin, Immunol, Infant, Infection, Influenza, Influenza virus, Influenza viruses, Karron, Maternal antibodies, Maternal antibody, Microbial, Monoclonal antibodies, Nasal wash, Nasopharyngeal secretion, Natural infection, Neutralizing, Neutralizing antibodies, Nonhuman primates, Ogra, Parainfluenza, Parainfluenza type, Parainfluenza virus type, Passive transfer, Pediatr, Peripheral blood, Previous infection, Primary infection, Primary role, Protective efficacy, Recombinant, Reinfection, Respiratory, Respiratory syncytial, Respiratory syncytial virus, Respiratory syncytial virus infection, Respiratory syncytial virus infections, Respiratory syncytial virus vaccine, Respiratory tract, Respiratory virus infection, Respiratory viruses, Routine immunizations, Seronegative, Seronegative chimpanzees, Seronegative infants, Seronegative subjects, Serum antibodies, Severe disease, Subclass, Subgroup, Syncytial, Syncytial virus, Syncytial virus infection, Taber, Third infections, Titre, Vaccine, Vaccine candidates, Vaccinee, Viral, Virus, Virus infection, Virus infections, Virus replication, Virus vaccines, Welliver, Young children, Young infants.
Abstract
Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.
Url:
DOI: 10.1016/S0264-410X(98)00103-0
Links to Exploration step
ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><author><name sortKey="Crowe Jr, James E" sort="Crowe Jr, James E" uniqKey="Crowe Jr J" first="James E." last="Crowe Jr.">James E. Crowe Jr.</name><affiliation><mods:affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: james.e.crowe@vanderbilt.edu</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0264-410X(98)00103-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001769</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001769</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><author><name sortKey="Crowe Jr, James E" sort="Crowe Jr, James E" uniqKey="Crowe Jr J" first="James E." last="Crowe Jr.">James E. Crowe Jr.</name><affiliation><mods:affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: james.e.crowe@vanderbilt.edu</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">14–15</biblScope><biblScope unit="page" from="1423">1423</biblScope><biblScope unit="page" to="1432">1432</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adult bone marrow transplant recipients</term><term>Antibody</term><term>Antibody response</term><term>Antibody responses</term><term>Antigenic</term><term>Antigenic variation</term><term>Attenuated</term><term>Attenuated influenza</term><term>Attenuated vaccines</term><term>Belshe</term><term>Bronchiolitis</term><term>Chanock</term><term>Chiba</term><term>Cotton rats</term><term>Crowe</term><term>Cytotoxic</term><term>Epidemiol</term><term>Experimental infection</term><term>Experimental studies</term><term>Glezen</term><term>Glycoprotein</term><term>Heterosubtypic immunity</term><term>High levels</term><term>Hlnl</term><term>Immun</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunity</term><term>Immunization</term><term>Immunogenicity</term><term>Immunoglobulin</term><term>Immunol</term><term>Infant</term><term>Infection</term><term>Influenza</term><term>Influenza virus</term><term>Influenza viruses</term><term>Karron</term><term>Maternal antibodies</term><term>Maternal antibody</term><term>Microbial</term><term>Monoclonal antibodies</term><term>Nasal wash</term><term>Nasopharyngeal secretion</term><term>Natural infection</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Nonhuman primates</term><term>Ogra</term><term>Parainfluenza</term><term>Parainfluenza type</term><term>Parainfluenza virus type</term><term>Passive transfer</term><term>Pediatr</term><term>Peripheral blood</term><term>Previous infection</term><term>Primary infection</term><term>Primary role</term><term>Protective efficacy</term><term>Recombinant</term><term>Reinfection</term><term>Respiratory</term><term>Respiratory syncytial</term><term>Respiratory syncytial virus</term><term>Respiratory syncytial virus infection</term><term>Respiratory syncytial virus infections</term><term>Respiratory syncytial virus vaccine</term><term>Respiratory tract</term><term>Respiratory virus infection</term><term>Respiratory viruses</term><term>Routine immunizations</term><term>Seronegative</term><term>Seronegative chimpanzees</term><term>Seronegative infants</term><term>Seronegative subjects</term><term>Serum antibodies</term><term>Severe disease</term><term>Subclass</term><term>Subgroup</term><term>Syncytial</term><term>Syncytial virus</term><term>Syncytial virus infection</term><term>Taber</term><term>Third infections</term><term>Titre</term><term>Vaccine</term><term>Vaccine candidates</term><term>Vaccinee</term><term>Viral</term><term>Virus</term><term>Virus infection</term><term>Virus infections</term><term>Virus replication</term><term>Virus vaccines</term><term>Welliver</term><term>Young children</term><term>Young infants</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>syncytial</json:string><json:string>attenuated</json:string><json:string>vaccine</json:string><json:string>respiratory syncytial virus</json:string><json:string>glycoprotein</json:string><json:string>immune</json:string><json:string>viral</json:string><json:string>neutralizing</json:string><json:string>chanock</json:string><json:string>seronegative</json:string><json:string>reinfection</json:string><json:string>crowe</json:string><json:string>parainfluenza</json:string><json:string>influenza</json:string><json:string>young children</json:string><json:string>subclass</json:string><json:string>respiratory syncytial virus infection</json:string><json:string>hlnl</json:string><json:string>subgroup</json:string><json:string>immunoglobulin</json:string><json:string>antibody response</json:string><json:string>immune responses</json:string><json:string>immunization</json:string><json:string>belshe</json:string><json:string>antigenic</json:string><json:string>immunol</json:string><json:string>ogra</json:string><json:string>antibody responses</json:string><json:string>welliver</json:string><json:string>pediatr</json:string><json:string>primary infection</json:string><json:string>respiratory viruses</json:string><json:string>cytotoxic</json:string><json:string>infection</json:string><json:string>virus</json:string><json:string>virus infection</json:string><json:string>glezen</json:string><json:string>vaccinee</json:string><json:string>karron</json:string><json:string>immune response</json:string><json:string>recombinant</json:string><json:string>immunogenicity</json:string><json:string>serum antibodies</json:string><json:string>epidemiol</json:string><json:string>taber</json:string><json:string>immun</json:string><json:string>microbial</json:string><json:string>young infants</json:string><json:string>natural infection</json:string><json:string>virus vaccines</json:string><json:string>antibody</json:string><json:string>syncytial virus</json:string><json:string>attenuated influenza</json:string><json:string>passive transfer</json:string><json:string>infant</json:string><json:string>respiratory syncytial</json:string><json:string>protective efficacy</json:string><json:string>neutralizing antibodies</json:string><json:string>nasal wash</json:string><json:string>high levels</json:string><json:string>maternal antibodies</json:string><json:string>seronegative subjects</json:string><json:string>syncytial virus infection</json:string><json:string>respiratory syncytial virus infections</json:string><json:string>adult bone marrow transplant recipients</json:string><json:string>experimental studies</json:string><json:string>severe disease</json:string><json:string>parainfluenza virus type</json:string><json:string>titre</json:string><json:string>chiba</json:string><json:string>bronchiolitis</json:string><json:string>routine immunizations</json:string><json:string>maternal antibody</json:string><json:string>vaccine candidates</json:string><json:string>influenza viruses</json:string><json:string>cotton rats</json:string><json:string>attenuated vaccines</json:string><json:string>previous infection</json:string><json:string>experimental infection</json:string><json:string>respiratory syncytial virus vaccine</json:string><json:string>seronegative infants</json:string><json:string>primary role</json:string><json:string>virus replication</json:string><json:string>parainfluenza type</json:string><json:string>monoclonal antibodies</json:string><json:string>antigenic variation</json:string><json:string>virus infections</json:string><json:string>peripheral blood</json:string><json:string>seronegative chimpanzees</json:string><json:string>respiratory virus infection</json:string><json:string>influenza virus</json:string><json:string>heterosubtypic immunity</json:string><json:string>respiratory tract</json:string><json:string>nasopharyngeal secretion</json:string><json:string>third infections</json:string><json:string>nonhuman primates</json:string><json:string>respiratory</json:string><json:string>immunity</json:string></teeft></keywords><author><json:item><name>James E. Crowe, Jr.</name><affiliations><json:string>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</json:string><json:string>E-mail: james.e.crowe@vanderbilt.edu</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Section 5—Enhancing infant protection through early immunization</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>respiratory syncytial virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parainfluenza virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>infant</value></json:item></subject><arkIstex>ark:/67375/6H6-7S3PBJ9D-B</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</abstract><qualityIndicators><score>9.316</score><pdfWordCount>8002</pdfWordCount><pdfCharCount>57102</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>614 x 857 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>193</abstractWordCount><abstractCharCount>1380</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><pmid><json:string>9711783</json:string></pmid><pii><json:string>S0264-410X(98)00103-0</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Proc. Natl. Acad. Sci. USA</title><language><json:string>unknown</json:string></language><volume>91</volume><pages><first>1386</first><last>1390</last></pages></serie><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1998</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0061-8</json:string></pii><volume>16</volume><issue>14–15</issue><pages><first>1423</first><last>1432</last></pages><genre><json:string>journal</json:string></genre><conference><json:item><name>Immunity in Early Life, Les Pensieres, Veyrier-du-Lac, Annecy, France 19971117 19971119</name></json:item></conference><editor><json:item><name>Claire-Anne Siegrist</name></json:item><json:item><name>Paul-Henri Lambert</name></json:item><json:item><name>Christine Biron</name></json:item><json:item><name>Pierre Meulien</name></json:item><json:item><name>Ethan Shevach</name></json:item><json:item><name>Ghislaine Sterkers</name></json:item><json:item><name>Peter Wright</name></json:item></editor></host><namedEntities><unitex><date><json:string>1960s</json:string><json:string>1998</json:string><json:string>19971117</json:string><json:string>1970s</json:string></date><geogName></geogName><orgName><json:string>Vanderbilt University</json:string><json:string>Division of Pediatric Infectious Diseases</json:string><json:string>Memorial Foundation, Goodlettsville, TN</json:string><json:string>Mucosal Pathogens Research Unit</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ghislaine Sterkers</json:string><json:string>Crowe</json:string><json:string>Pierre Meulien</json:string><json:string>Ann Arbor</json:string><json:string>Paul-Henri Lambert</json:string><json:string>J.E. Crowe</json:string><json:string>Peter Wright</json:string><json:string>BeemX</json:string><json:string>James E.Crowe</json:string><json:string>B. Analysis</json:string><json:string>Christine Biron</json:string><json:string>Ethan Shevach</json:string></persName><placeName><json:string>NY.</json:string><json:string>Beijing</json:string><json:string>Kawasaki</json:string><json:string>York</json:string><json:string>TN</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Medical Center North, 1161</json:string><json:string>Hendry et al.</json:string><json:string>Vaccine 1998</json:string><json:string>Hall et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-7S3PBJ9D-B</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1016/S0264-410X(98)00103-0</json:string></doi><id>1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1998</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title><author xml:id="author-0000"><persName><forename type="first">James E.</forename><surname>Crowe, Jr.</surname></persName><email>james.e.crowe@vanderbilt.edu</email><affiliation>Author to whom correspondence should be addressed: Tel.: 001 615 322 2250; Fax: 001 615 343 9723</affiliation><affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</affiliation></author><idno type="istex">1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4</idno><idno type="ark">ark:/67375/6H6-7S3PBJ9D-B</idno><idno type="DOI">10.1016/S0264-410X(98)00103-0</idno><idno type="PII">S0264-410X(98)00103-0</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0061-8</idno><meeting><addName>Immunity in Early Life, Les Pensieres, Veyrier-du-Lac, Annecy, France</addName><date>19971117</date><date>19971119</date></meeting><editor xml:id="book-author-0000"><persName>Claire-Anne Siegrist</persName></editor><editor xml:id="book-author-0001"><persName>Paul-Henri Lambert</persName></editor><editor xml:id="book-author-0002"><persName>Christine Biron</persName></editor><editor xml:id="book-author-0003"><persName>Pierre Meulien</persName></editor><editor xml:id="book-author-0004"><persName>Ethan Shevach</persName></editor><editor xml:id="book-author-0005"><persName>Ghislaine Sterkers</persName></editor><editor xml:id="book-author-0006"><persName>Peter Wright</persName></editor><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">14–15</biblScope><biblScope unit="page" from="1423">1423</biblScope><biblScope unit="page" to="1432">1432</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</p></abstract><textClass><keywords scheme="keyword"><list><head>article-category</head><item><term>Section 5—Enhancing infant protection through early immunization</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>respiratory syncytial virus</term></item><item><term>parainfluenza virus</term></item><item><term>vaccines</term></item><item><term>infant</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>98001030</aid><ce:pii>S0264-410X(98)00103-0</ce:pii><ce:doi>10.1016/S0264-410X(98)00103-0</ce:doi><ce:copyright type="unknown" year="1998"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Section 5—Enhancing infant protection through early immunization</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</ce:title><ce:author-group><ce:author><ce:given-name>James E.</ce:given-name><ce:surname>Crowe</ce:surname><ce:suffix>Jr.</ce:suffix><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:e-address>james.e.crowe@vanderbilt.edu</ce:e-address></ce:author><ce:affiliation><ce:textfn>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Author to whom correspondence should be addressed: Tel.: 001 615 322 2250; Fax: 001 615 343 9723</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability <ce:italic>in vivo</ce:italic>. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>respiratory syncytial virus</ce:text></ce:keyword><ce:keyword><ce:text>parainfluenza virus</ce:text></ce:keyword><ce:keyword><ce:text>vaccines</ce:text></ce:keyword><ce:keyword><ce:text>infant</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines</title></titleInfo><name type="personal"><namePart type="given">James E.</namePart><namePart type="family">Crowe, Jr.</namePart><affiliation>Division of Pediatric Infectious Diseases, Vanderbilt University Medical School, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA</affiliation><affiliation>E-mail: james.e.crowe@vanderbilt.edu</affiliation><description>Author to whom correspondence should be addressed: Tel.: 001 615 322 2250; Fax: 001 615 343 9723</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Respiratory viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIV), and the influenza viruses cause severe lower respiratory tract diseases in infants and children throughout the world. Experimental live attenuated vaccines for each of these viruses are being developed for intranasal administration in the first weeks or months of life. A variety of promising RSV, PIV-3, and influenza virus vaccine strains have been developed by classical biological methods, evaluated extensively in preclinical and clinical studies, and shown to be attenuated and genetically stable. The ongoing clinical evaluation of these vaccine candidates, coupled with recent major advances in the ability to develop genetically engineered viruses with specified mutations, may allow the rapid development of respiratory virus strains that possess ideal levels of replicative capacity and genetic stability in vivo. A major remaining obstacle to successful immunization of infants against respiratory virus associated disease may be the relatively poor immune response of very young infants to primary virus infection. This paper reviews the immune correlates of protection against disease caused by these viruses, immune responses of infants to naturally-acquired infection, and immune responses of infants to experimental infection with candidate vaccine viruses.</abstract><note type="content">Section title: Paper</note><subject><genre>article-category</genre><topic>Section 5—Enhancing infant protection through early immunization</topic></subject><subject><genre>Keywords</genre><topic>respiratory syncytial virus</topic><topic>parainfluenza virus</topic><topic>vaccines</topic><topic>infant</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><name type="conference"><namePart>Immunity in Early Life, Les Pensieres, Veyrier-du-Lac, Annecy, France</namePart><namePart type="date">19971117</namePart><namePart type="date">19971119</namePart></name><name type="personal"><namePart>Claire-Anne Siegrist</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Paul-Henri Lambert</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Christine Biron</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Pierre Meulien</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Ethan Shevach</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Ghislaine Sterkers</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Peter Wright</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0061-8</identifier><part><date>1998</date><detail type="issue"><title>Immunity in Early Life, Les Pensieres, Veyrier-du-Lac, Annecy, France</title></detail><detail type="volume"><number>16</number><caption>vol.</caption></detail><detail type="issue"><number>14–15</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1351</start><end>1485</end></extent><extent unit="pages"><start>1423</start><end>1432</end></extent></part></relatedItem><identifier type="istex">1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4</identifier><identifier type="ark">ark:/67375/6H6-7S3PBJ9D-B</identifier><identifier type="DOI">10.1016/S0264-410X(98)00103-0</identifier><identifier type="PII">S0264-410X(98)00103-0</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-7S3PBJ9D-B/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001769 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001769 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1455B9E8FAFEC189D10361F23B31E5DD0C21B2A4
|texte= Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
}}
| This area was generated with Dilib version V0.6.33. |  |